Progress and controversies: Radiation therapy for prostate cancer

Answer questions and earn CME/CNE

[1]  Anthony L Zietman,et al.  The Titanic and the Iceberg: prostate proton therapy and health care economics. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  David C. Miller,et al.  Adherence to performance measures and outcomes among men treated for prostate cancer. , 2014, The Journal of urology.

[3]  J. Fowler.  The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[4]  J. Fowler,et al.  Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. , 2011, International journal of radiation oncology, biology, physics.

[5]  M. Zelefsky,et al.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[6]  M. Santoro,et al.  Stereotactic body radiotherapy for organ-confined prostate cancer , 2010, BMC urology.

[7]  D. Kuban,et al.  Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? , 2011, International journal of radiation oncology, biology, physics.

[8]  D. Kuban,et al.  Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation , 2010 .

[9]  Gary E. Day,et al.  Redefining Health Care: Creating Value-Based Competition on Results , 2006 .

[10]  I. Kaplan,et al.  Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma , 2012, Cancer.

[11]  A. D'Amico,et al.  Patient and treatment factors associated with complications after prostate brachytherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Oliver Sartor,et al.  Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. , 2013, International journal of radiation oncology, biology, physics.

[13]  Gary Luxton,et al.  Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. , 2004, International journal of radiation oncology, biology, physics.

[14]  Zuofeng Li,et al.  Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[15]  R. Stock,et al.  Disease-specific survival following the brachytherapy management of prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[16]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Stoyanova,et al.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[19]  Erwin A. Blackstone,et al.  Redefining Health Care: Creating Value-Based Competition on Results , 2007 .

[20]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[21]  R. DiPaola,et al.  Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.

[22]  A. D'Amico,et al.  Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.

[23]  R. Uzzo,et al.  Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[24]  C. Gross,et al.  Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[26]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[27]  J. Pouliot,et al.  Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. , 2008, International journal of radiation oncology, biology, physics.

[28]  Lidia Strigari,et al.  A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[29]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Kestin,et al.  Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the α/β Ratio of Prostate Cancer , 2007 .

[31]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[32]  Jack Clark,et al.  Symptom Indexes to Assess Outcomes of Treatment for Early Prostate Cancer , 2001, Medical care.

[33]  David C. Miller,et al.  Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. , 2014, The Journal of urology.

[34]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Philip W. Kantoff,et al.  Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer , 2013, Annals of Internal Medicine.

[36]  Ronald C. Chen,et al.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. , 2012, JAMA.

[37]  M. Zelefsky,et al.  Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. , 2014, The Journal of urology.

[38]  P. Scardino,et al.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[40]  A. Zietman,et al.  Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer , 2013, Cancer.

[41]  L. Verhey,et al.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.

[42]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Manola,et al.  Using patient‐reported outcomes to assess and improve prostate cancer brachytherapy , 2014, BJU international.

[44]  M. Steinberg,et al.  Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. , 2013, International journal of radiation oncology, biology, physics.

[45]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[46]  Y. Yamada,et al.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. , 2013, European urology.

[47]  J. Cuzick,et al.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort , 2012, British Journal of Cancer.

[48]  Michael J. Zelefsky,et al.  Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[49]  J. Bahary,et al.  Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial. , 2013 .

[50]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[51]  Ronald C. Chen,et al.  Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. , 2011, The Journal of urology.

[52]  W. Shih,et al.  Late gastrointestinal toxicities following radiation therapy for prostate cancer. , 2011, European urology.

[53]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[54]  A. Trofimov,et al.  Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer , 2009, Cancer journal.

[55]  J. Tepper.  Protons and parachutes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[57]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Lubeck,et al.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.

[59]  J. Efstathiou,et al.  Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[60]  John T. Wei,et al.  Prediction of erectile function following treatment for prostate cancer. , 2011, JAMA.

[61]  D. Meltzer,et al.  The role of anxiety in prostate carcinoma , 2005, Cancer.

[62]  M. Kattan,et al.  Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. , 2012, The Journal of urology.

[63]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[64]  D. Siemens.  Radical prostatectomy or watchful waiting in early prostate cancer? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[65]  Jean M. Mitchell.  Urologists' use of intensity-modulated radiation therapy for prostate cancer. , 2013, The New England journal of medicine.

[66]  W. Sause,et al.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. , 1988, International journal of radiation oncology, biology, physics.

[67]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, The Lancet.

[68]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[69]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[70]  M. Porter.  A strategy for health care reform--toward a value-based system. , 2009, The New England journal of medicine.

[71]  Alexei Trofimov,et al.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. , 2007, International journal of radiation oncology, biology, physics.

[72]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[73]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[74]  A. Markoe,et al.  Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. , 2004, International journal of radiation oncology, biology, physics.

[75]  Jeremy MG Taylor,et al.  Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[76]  B. Haffty,et al.  Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer , 2010 .

[77]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[78]  J. Lee,et al.  Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. , 2008, European urology.

[79]  A. D'Amico,et al.  Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[80]  U. Patel.  Histology core‐specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate , 2013, BJU international.

[81]  Amitabh Chandra,et al.  The sources of the SGR "hole". , 2012, The New England journal of medicine.

[82]  P. Ghadjar,et al.  Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2011, Cancer.

[83]  Sylvie Chabaud,et al.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  A. Zietman,et al.  The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. , 1997, The cancer journal from Scientific American.

[85]  D. Moses,et al.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. , 2014, The Journal of urology.

[86]  Thomas Hambrock,et al.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. , 2011, Radiology.

[87]  Tom Pickles,et al.  The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[88]  A. D'Amico,et al.  Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. , 2009, International journal of radiation oncology, biology, physics.

[89]  A. D'Amico,et al.  Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[91]  Ansgar Malich,et al.  Definition of the CTV Prostate in CT and MRI by Using CT–MRI Image Fusion in IMRT Planning for Prostate Cancer , 2011, Strahlentherapie und Onkologie.

[92]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[93]  A. D'Amico,et al.  Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death , 2010, BJU international.

[94]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[95]  P. Johnstone,et al.  Proton therapy expansion under current United States reimbursement models. , 2014, International journal of radiation oncology, biology, physics.

[96]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[97]  M. Cooperberg,et al.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  C. Lawton.  Duration of Androgen Suppression in the Treatment of Prostate Cancer , 2010 .

[99]  S. Ramsey,et al.  Why do men choose one treatment over another? , 2006, Cancer.

[100]  A. Shindel.  Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer: The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial , 2014 .

[101]  Andrzej Niemierko,et al.  Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. , 2010, JAMA.

[102]  David Forman,et al.  Integrating Patient Reported Outcomes With Clinical Cancer Registry Data: A Feasibility Study of the Electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) System , 2013, Journal of medical Internet research.

[103]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[104]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[105]  C. D’Este,et al.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. , 2011, The Lancet. Oncology.

[106]  G E Hanks,et al.  Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. , 1992, International journal of radiation oncology, biology, physics.

[107]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[108]  D P Dearnaley,et al.  Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[109]  I. Kaplan,et al.  Hypofractionated Stereotactic Body Radiotherapy in Low Risk Prostate Adenocarcinoma: Preliminary Results of a Multi-Institutional Phase I Feasibility Trial , 2011 .

[110]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[111]  J. Galvin,et al.  Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. , 2013, International journal of radiation oncology, biology, physics.

[112]  H. Sandler,et al.  Late toxicity and biochemical recurrence after external‐beam radiotherapy combined with permanent‐source prostate brachytherapy , 2007, Cancer.

[113]  J. Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.

[114]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[115]  P. Wiklund,et al.  Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes , 2014, BMJ : British Medical Journal.

[116]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[117]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[118]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Ronald C. Chen,et al.  Patient‐reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial , 2012, BJU international.

[120]  K. Wallner,et al.  There Is a Wide Range of Predictive Dosimetric Factors for I-125 and Pd-103 Prostate Brachytherapy , 2008, American journal of clinical oncology.

[121]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[122]  Ronald C. Chen,et al.  Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  M. Kahn,et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma , 1997, Cancer.

[124]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  A. Zietman,et al.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. , 2000, JAMA.

[127]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[128]  R Mohan,et al.  Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. , 1996, International journal of radiation oncology, biology, physics.

[129]  William Preston,et al.  Proton therapy for prostate cancer: the initial Loma Linda University experience. , 2004, International journal of radiation oncology, biology, physics.

[130]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  D. Brenner,et al.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery , 2000, Cancer.

[132]  A. D'Amico,et al.  Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  William L. Welbourn,et al.  Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[134]  Lawrence B Marks,et al.  Radiation dose-volume effects of the urinary bladder. , 2010, International journal of radiation oncology, biology, physics.

[135]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[136]  G. Gustafson,et al.  High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. , 2004, The Journal of urology.

[137]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[138]  S. Lipsitz,et al.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  N. Mohideen,et al.  Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. , 2009, The journal of sexual medicine.

[140]  S. Daneshmand,et al.  Androgen deprivation therapy: evidence‐based management of side effects , 2013, BJU international.

[141]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[142]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[143]  K. Cooney,et al.  Risk of second primary tumors in men diagnosed with prostate cancer: A population‐based cohort study , 2014, Cancer.

[144]  W. Lee,et al.  Hypofractionation for clinically localized prostate cancer. , 2013, Seminars in radiation oncology.

[145]  Y. Lotan,et al.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  C. King.  The timing of salvage radiotherapy after radical prostatectomy: a systematic review. , 2012, International journal of radiation oncology, biology, physics.

[147]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[148]  M. Cooperberg,et al.  Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. , 2009, Journal of the National Cancer Institute.

[149]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[150]  G. Duchesne,et al.  Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.